ACADIA Pharmaceuticals Inc. (ACAD) and CRISPR Therapeutics AG (NASDAQ:CRSP) Comparison side by side

Both ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and CRISPR Therapeutics AG (NASDAQ:CRSP) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals Inc. 223.81M 17.26 245.19M -1.44 0.00
CRISPR Therapeutics AG 3.12M 646.63 164.98M -3.43 0.00

Table 1 highlights ACADIA Pharmaceuticals Inc. and CRISPR Therapeutics AG’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals Inc. -109.55% -77.1% -66.6%
CRISPR Therapeutics AG -5,287.82% -48.3% -38%


The Current Ratio of ACADIA Pharmaceuticals Inc. is 8.8 while its Quick Ratio stands at 8.8. The Current Ratio of rival CRISPR Therapeutics AG is 16.8 and its Quick Ratio is has 16.8. CRISPR Therapeutics AG is better equipped to clear short and long-term obligations than ACADIA Pharmaceuticals Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for ACADIA Pharmaceuticals Inc. and CRISPR Therapeutics AG.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ACADIA Pharmaceuticals Inc. 0 3 6 2.67
CRISPR Therapeutics AG 0 0 0 0.00

ACADIA Pharmaceuticals Inc. has an average target price of $33.89, and a 26.22% upside potential.

Insider & Institutional Ownership

Roughly 98.64% of ACADIA Pharmaceuticals Inc. shares are held by institutional investors while 46.8% of CRISPR Therapeutics AG are owned by institutional investors. About 0.1% of ACADIA Pharmaceuticals Inc.’s share are held by insiders. Competitively, insiders own roughly 2.4% of CRISPR Therapeutics AG’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ACADIA Pharmaceuticals Inc. 13.05% 17.87% 30.78% 86.2% 16.84% 66.05%
CRISPR Therapeutics AG 0.68% 23.1% 6.11% -23.48% -14.22% 39.73%

For the past year ACADIA Pharmaceuticals Inc. was more bullish than CRISPR Therapeutics AG.


ACADIA Pharmaceuticals Inc. beats CRISPR Therapeutics AG on 6 of the 11 factors.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.